59 reports

  • 12.1 BIBLIOGRAPHY

Heath, P. (##) ' Ocular Lymphomas', Transactions of the American Ophthalmological Hessen, M. and Akpek, E.

  • Ophthalmology
  • Forecast
  • Allergan plc
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.

Synthetic prostaglandin analogs have a large number of clinical applications; the treatment of glaucoma is one of the major ones.

  • Ophthalmology
  • Allergan plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

Drugs For Respiratory Diseases P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A

  • Ophthalmology
  • Market Size
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • idiopathic uveitis usually involve the anterior segment of the eye, but other conditions like Beht's

They may have a higher percentage of lymphoma, [but] who knows.

  • Ophthalmology
  • AbbVie Inc.
  • Clearside Biomedical, Inc.
  • pSivida Corp.
  • Santen Pharmaceutical Co., Ltd.

" Stelara doesn' t have a black box warning, it doesn' t have a lymphoma risk, it doesn' t have a cancer risk, it doesn' t have an increased infection risk.

  • Ophthalmology
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.

Journal of Autoimmunity; ##(##): ##-##.

  • Ophthalmology
  • Pathology
  • Japan
  • United States
  • Forecast

Initially, it stimulates the DC, leading to the activation of natural killer (NK) cells that are capable of destroying lymphomas.

  • Cell Therapy
  • Ophthalmology
  • Pharmaceutical
  • Therapy
  • Ohr Pharmaceutical Inc.

You can easily book an appointment with one online.

  • Ophthalmology
  • Baxter International Inc.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Spectrum Pharmaceuticals, Inc.

It binds to the receptor FLT##/ VEGFR-##.

  • Ophthalmology
  • United States
  • World
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.

It has three drug candidates in development, CUDC-## for diffuse large B-cell lymphoma (DLBCL) and solid tumors; CA-## for advanced solid tumors or lymphoma; and CA-## for advanced non-Hodgkin lymphomas.

  • Immunology
  • Ophthalmology
  • Pharmaceutical
  • Therapy
  • Genentech, Inc.
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Drug Profiles

It is a ligand for VEGFR-## (vascular endothelial growth factor receptor ##) and NRP-## (neuropilin-##).

  • Ophthalmology
  • Therapy
  • World
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.

And NK-## Protein exhibited inhibition of growth, metastasis and angiogenesis in lymphoma mice models when used as a protein therapy.

  • Cell Therapy
  • Ophthalmology
  • Pharmaceutical
  • Research And Development
  • Therapy
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Drug Profiles

It is a ligand for VEGFR-## (vascular endothelial growth factor receptor ##) and NRP-## (neuropilin-##).

  • Eye Disease
  • Ophthalmology
  • Pharmaceutical
  • Targeted Therapy
  • Therapy

It binds to the receptor FLT##/ VEGFR-##.

  • Ophthalmology
  • United States
  • World
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.
  • 3 Research Methodology

RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION) ## ##. ##. ##. ## U.

  • Ophthalmology
  • North America
  • United States
  • World
  • Demand
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Monoclonal Antibody
  • Ophthalmology
  • Therapy
  • World
  • Product Initiative

An increased sFlt-##/ mFlt-## ratio in the Flt morpholino group was seen with RT-PCR.

  • Ophthalmology
  • Therapy
  • United States
  • World
  • Product Initiative

For more information, please contact sales@lamerie. com Related Competitor Analysis Reports Competitor Analysis: Focal Adhesion Kinase (FAK) Inhibitor Competitor Analysis: Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors Competitor Analysis: Anaplastic Lymphoma Kinase (ALK) Inhibitors Competi

  • Biosimilar
  • Ophthalmology
  • Targeted Therapy
  • Therapy
  • United States
  • CVXL-0074 - DRUG PROFILE

-based multicenter, ##:## randomized, double-masked, vehicle-controlled trial is enrolling patients who exhibit chronic signs and symptoms of allergic conjunctivitis.

  • Ophthalmic Solution
  • Ophthalmology
  • Pharmaceutical
  • United States
  • Product Initiative
  • Target
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Ophthalmology
  • World
  • Product Initiative
  • Novartis AG

About two hundred patients were randomly assigned into one of two treatment arms in a ##:## ratio.

  • Biosimilar
  • Ophthalmology
  • Pharmaceutical
  • Therapy
  • EyeGate Pharmaceuticals, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Ophthalmology
  • Therapy
  • World
  • Product Initiative
  • Novartis AG

The prominent features of this report are - ##.

  • Ophthalmology
  • OTC
  • Therapy
  • World
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Drug Development
  • Ophthalmology
  • World
  • Novartis AG

The prominent features of this report are - ##.

  • Clinical Trial
  • Eye Disease
  • Ophthalmology
  • Therapy
  • Biogen Idec Inc.
  • Target

The prominent features of this report are - ##.

  • Ophthalmology
  • Therapy
  • World
  • Product Initiative
  • Novartis AG

About two hundred patients were randomly assigned into one of two treatment arms in a ##:## ratio.

  • Ophthalmology
  • Pharmaceutical
  • United States
  • Product Initiative
  • Clearside Biomedical, Inc.

This trial is designed to assess safety, tolerability and antitumor activity of HBI-## in patients with advanced solid tumors and lymphomas.

  • Ophthalmology
  • Pharmaceutical
  • United States
  • Company
  • Quintiles Transnational Holdings Inc.

This trial is designed to assess safety, tolerability and antitumor activity of HBI-## in patients with advanced solid tumors and lymphomas.

  • Ophthalmology
  • Pharmaceutical
  • United States
  • Company
  • Quintiles Transnational Holdings Inc.

About two hundred patients wererandomly assigned into one of two treatment arms in a ##:## ratio.

  • Medical Biotechnology
  • Ophthalmology
  • Pharmaceutical
  • Therapy
  • United States